The Siegel Rare Neuroimmune Association’s Eclipse Fund for research is excited to share the establishment of The Progress Grant for NMOSD made possible by a research grant from Horizon Therapeutics.
The Eclipse Fund in memory of Pauline H. Siegel was established to support and accelerate research that will directly impact quality of life for the members of our community.
The aim of this grant is to fund research aimed to improve understanding of neuromyelitis optica spectrum disorder (NMOSD) focused on specifically Asian and African American populations. In studies on NMOSD, we see that this disorder disproportionately affects those who are Black or Asian, unlike MS, which is more common among those who are White. Also, Black and Asian patients seem to be younger at onset and have more brain symptoms or MRI abnormalities than White patients.
The purpose of the Progress Grant for NMOSD is to help the broader NMOSD community understand how to improve diagnosis, treatment and quality of life of people with NMOSD. Research projects may focus on access to care, mental and psychosocial aspects of living with NMOSD, clinical differences, improving diagnosis and clinical care, therapeutics, or basic science projects.
The Progress Grant for NMOSD will award one $25,000 grant award to conduct original research. All funds will be used to support the research directly. SRNA does not support indirect institutional costs.
Grants are made to organizations on behalf of a named Principal Investigator. Applicants must provide a research project consistent with the goals of the award that helps advance the field forward.
Open Date – April 5, 2021
Closing Date – June 30, 2021
Review and Board approval – July-August 2021
Awards announced – September 2021
Proposals submitted through the online form should provide a detailed description of the research or clinical project that will be partially or fully supported by the grant and a budget providing details of the estimated costs. Proposals are reviewed by our basic and clinical scientists and experts on SRNA’s Medical and Scientific Council. Additional expertise may be sought from ad-hoc reviewers to ensure comprehensive scientific review. Applications will be reviewed based on innovation, scientific rigor and alignment with the goals of the grant. Potential conflicts of interest for reviewers and applicants must be mentioned in the application and declared prior to the review and will be recused from the review process.
Recommendations for funding are made to the Board of Directors of SRNA. The final approval for funding is provided by the Board.
Funding from SRNA may not be used to cover any indirect costs.
As reporting requirements, SRNA would require two articles (as six-month reports) for SRNA’s Magazine, which describe the progress and findings from the research. We also require a final report be submitted detailing the expenditure of the funds and a short summary that we will publish on the SRNA website. SRNA should be acknowledged in any publications of research results that were supported by the grant.
The Siegel Rare Neuroimmune Association funds clinical and biomedical research in order to better understand the causes of Acute Disseminated Encephalomyelitis, Acute Flaccid Myelitis, MOG Antibody Disease, Neuromyelitis Optica Spectrum Disorder, Optic Neuritis, and Transverse Myelitis; and to advance early diagnosis, treatment, and cures. The main output of this research is new knowledge. To ensure this knowledge can be accessed, read, applied, and built upon in fulfillment of our goals, the Siegel Rare Neuroimmune Association expects its researchers to publish their findings in peer-reviewed journals.
In addition, it is a condition of the Siegel Rare Neuroimmune Association’s funding that a copy of all funded research outputs, in the form of final, peer-reviewed manuscripts, must be delivered to the Siegel Rare Neuroimmune Association upon acceptance. These manuscripts will be made publicly available on the Siegel Rare Neuroimmune Association website no later than 12 months after the official date of publication.
This requirement applies to all Siegel Rare Neuroimmune Association grants awarded after January 1, 2012.
The policy is developed with the Scholarly Publishing and Academic Resources Coalition (SPARC) and is based on the policy developed by Autism Speaks, with that organization’s permission.
Applications were due on June 30th, 2021, and are currently closed.